poisar

Stocks · News reference

SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement

    SRX Global commented on industry activity in engineered T-cell therapies following Pfizer's $330 million upfront deal with Starna Therapeutics for pre-IND CAR-T programs. SRX is proceeding with its pending acquisition of CERo Therapeutics, which is advancing CER-1236, a clinical-stage engineered T-cell therapy currently in Phase 1/1b CERTAIN-T trials with seven patients dosed and no dose-limiting toxicities reported.